BRPI0923199A2 - métodos e composições para detecção de anticorpos com fixação de complemento. - Google Patents

métodos e composições para detecção de anticorpos com fixação de complemento.

Info

Publication number
BRPI0923199A2
BRPI0923199A2 BRPI0923199A BRPI0923199A BRPI0923199A2 BR PI0923199 A2 BRPI0923199 A2 BR PI0923199A2 BR PI0923199 A BRPI0923199 A BR PI0923199A BR PI0923199 A BRPI0923199 A BR PI0923199A BR PI0923199 A2 BRPI0923199 A2 BR PI0923199A2
Authority
BR
Brazil
Prior art keywords
compositions
methods
fixing antibodies
detecting complement
complement
Prior art date
Application number
BRPI0923199A
Other languages
English (en)
Inventor
Dolly B Tyan
Ge Chen
Original Assignee
Trustees For The Leland Stanford Junior University Board Of
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Trustees For The Leland Stanford Junior University Board Of filed Critical Trustees For The Leland Stanford Junior University Board Of
Publication of BRPI0923199A2 publication Critical patent/BRPI0923199A2/pt
Publication of BRPI0923199B1 publication Critical patent/BRPI0923199B1/pt
Publication of BRPI0923199B8 publication Critical patent/BRPI0923199B8/pt

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854Immunoglobulins
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54313Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being characterised by its particulate form
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54313Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being characterised by its particulate form
    • G01N33/54326Magnetic particles
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701Details
    • G01N2333/4716Complement proteins, e.g. anaphylatoxin, C3a, C5a
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705Assays involving receptors, cell surface antigens or cell surface determinants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Rehabilitation Therapy (AREA)
  • Rheumatology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
BRPI0923199A 2008-12-01 2009-11-25 método para determinar a presença de anticorpos de fixação de complemento BRPI0923199B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11894908P 2008-12-01 2008-12-01
US61/118,949 2008-12-01
PCT/US2009/065984 WO2010065425A1 (en) 2008-12-01 2009-11-25 Methods and compositions for detection of complement fixing antibodies

Publications (3)

Publication Number Publication Date
BRPI0923199A2 true BRPI0923199A2 (pt) 2016-02-16
BRPI0923199B1 BRPI0923199B1 (pt) 2020-10-20
BRPI0923199B8 BRPI0923199B8 (pt) 2021-07-27

Family

ID=42233567

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0923199A BRPI0923199B8 (pt) 2008-12-01 2009-11-25 método para determinar a presença de anticorpos de fixação de complemento

Country Status (8)

Country Link
US (1) US10338080B2 (pt)
EP (2) EP2353005B1 (pt)
JP (2) JP5792626B2 (pt)
CN (2) CN105866426B (pt)
AU (1) AU2009322607B2 (pt)
BR (1) BRPI0923199B8 (pt)
CA (1) CA2740192C (pt)
WO (1) WO2010065425A1 (pt)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3722320A3 (en) 2012-10-25 2020-12-30 Bioverativ USA Inc. Anti-complement c1s antibodies and uses thereof
DK2914291T3 (da) 2012-11-02 2022-05-16 Bioverativ Usa Inc Anti-komplement-c1s-antistoffer og anvendelser deraf
WO2014151763A1 (en) * 2013-03-14 2014-09-25 The Board Of Trustees Of The Leland Stanford Junior University Methods of detecting donor-specific antibodies and systems for practicing the same
WO2014160376A1 (en) * 2013-03-14 2014-10-02 The Board Of Trustees Of The Leland Stanford Junior University Methods of detecting complement fixing and non-complement fixing antibodies and systems for practicing the same
DK3019240T3 (da) 2013-07-09 2024-06-03 Annexon Inc Anti-komplementfaktor C1Q antistoffer og anvendelser deraf
SI3215527T1 (sl) * 2014-11-05 2025-04-30 Annexon, Inc. Humanizirana protitelesa proti komplementnemu faktorju C1q in njihova uporaba
CA2981321A1 (en) 2015-04-06 2016-10-13 True North Therapeutics, Inc. Humanized anti-c1s antibodies and methods of use thereof
US10527613B2 (en) 2015-11-10 2020-01-07 The Board Of Trustees Of The Leland Stanford Junior University Biomarker detection methods and systems and kits for practicing same
EP3380518B1 (en) 2015-11-24 2026-03-25 Annexon, Inc. Anti-complement factor c1q fab fragments and uses thereof
CA3010587C (en) 2015-12-03 2021-08-17 NJ Sharing Network Igg subtyping assay for identifying transplantable tissue samples
EP3239711B1 (en) 2016-04-27 2019-12-25 JIMRO Co., Ltd. Method for measuring anti-drug antibody
WO2017187656A1 (ja) * 2016-04-27 2017-11-02 株式会社Jimro 抗医薬品抗体の測定方法
CN110300520B (zh) 2016-10-12 2022-10-04 美国比奥维拉迪维股份有限公司 抗C1s抗体及其使用方法
US20190383805A1 (en) * 2017-01-25 2019-12-19 Northeastern University Electrochemical Antibody-Based Biosensor
CN114910635B (zh) * 2017-10-26 2025-05-02 科美诊断技术股份有限公司 一种无基质效应的均相免疫检测试剂盒及其应用
CN107976535B (zh) * 2017-11-03 2020-03-20 科美诊断技术股份有限公司 一种检测样本中目标IgM抗体的均相免疫检测试剂盒及其使用方法和应用
CN109991405B (zh) * 2017-12-29 2023-01-24 上海索昕生物科技有限公司 一种免疫检测试剂盒及其应用
JP7153494B2 (ja) * 2018-07-27 2022-10-14 シスメックス株式会社 生体粒子の測定方法、非特異シグナルの検出方法、生体粒子測定方法及び生体粒子を検出するための試薬キット
JP7153493B2 (ja) * 2018-07-27 2022-10-14 シスメックス株式会社 生体粒子の測定方法、非特異シグナルの検出方法、生体粒子測定方法及び生体粒子を検出するための試薬キット
DE202020006093U1 (de) * 2019-05-06 2025-04-09 The Regents Of The University Of California Nicht-HLA-Marker der Transplantatabstoßung
CN111812336A (zh) * 2020-08-10 2020-10-23 苏州康和顺医疗技术有限公司 用于检测冠状病毒抗体的检测试剂盒及其制备方法
EP4226155A1 (en) * 2020-10-09 2023-08-16 Takeda Vaccines, Inc. Methods for determining complement-fixing antibodies
US20240142451A1 (en) * 2021-03-31 2024-05-02 Takeda Vaccines, Inc. Methods for characterizing the immune response of a subject to a dengue virus composition
EP4089413A1 (en) * 2021-05-12 2022-11-16 Cisbio Bioassays Method for determining the binding of an antibody to the complement component 1q (c1q)
US12486322B2 (en) 2021-12-13 2025-12-02 Annexon, Inc. Anti-complement factor C1q antibodies with single binding arms and uses thereof
CN118604345A (zh) * 2024-05-31 2024-09-06 上海览屹医药科技有限公司 酶联免疫方法测定单克隆抗体浓度
CN120142127A (zh) * 2025-05-16 2025-06-13 上海荻硕贝肯基因科技有限公司 一种供者特异性抗体的检测方法

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1247080A (en) 1983-03-08 1988-12-20 Commonwealth Serum Laboratories Commission Antigenically active amino acid sequences
US5035995A (en) * 1984-10-02 1991-07-30 Calpis Food Industry Co., Ltd. Test method involving substance-conjugated complement component C1q
JPS6184560A (ja) * 1984-10-02 1986-04-30 Karupisu Shokuhin Kogyo Kk 補体結合性抗体の測定法
JPS61245060A (ja) 1985-04-23 1986-10-31 Takara Shuzo Co Ltd ヒト補体1q定量用キツト及び定量法
JPS6225994A (ja) * 1985-05-30 1987-02-03 ジエネテイツク システムズ コ−ポレイシヨン Hlaタイプ分け用モノクロ−ナル抗体
IL84160A0 (en) * 1986-10-16 1988-03-31 Vasocor Method and kit for immune complex assay
US5176998A (en) 1986-12-01 1993-01-05 The Scripps Research Institute Cell surface antigen detection method
US5223397A (en) 1991-06-05 1993-06-29 Sangstat Medical Corporation Soluble hla cross-match
US5270169A (en) * 1992-06-23 1993-12-14 Sangstat Medical Corporation Detection of HLA antigen-containing immune complexes
AU687010B2 (en) 1992-07-17 1998-02-19 Dana-Farber Cancer Institute Method of intracellular binding of target molecules
US5851829A (en) 1993-07-16 1998-12-22 Dana-Farber Cancer Institute Method of intracellular binding of target molecules
GB9502112D0 (en) 1995-02-03 1995-03-22 British Biocell Int Assay device and method
US6159748A (en) * 1995-03-13 2000-12-12 Affinitech, Ltd Evaluation of autoimmune diseases using a multiple parameter latex bead suspension and flow cytometry
US5948627A (en) 1997-05-30 1999-09-07 One Lambda Immunobead flow cytometric detection of anti-HLA panel-reactive antibody
NZ516848A (en) 1997-06-20 2004-03-26 Ciphergen Biosystems Inc Retentate chromatography apparatus with applications in biology and medicine
AU759779B2 (en) 1997-10-31 2003-05-01 Genentech Inc. Methods and compositions comprising glycoprotein glycoforms
CN1423130A (zh) 2002-04-26 2003-06-11 帕弗瑞生物技术(北京)有限公司 流式测定固定补体抗体的hla交叉配型方法和试剂盒
CN1444044A (zh) 2002-06-18 2003-09-24 帕弗瑞生物技术(北京)有限公司 以酶联免疫测定为基础的hla补体依赖性细胞毒性抗体检测方法和试剂盒
TW200508609A (en) 2003-07-15 2005-03-01 Bioarray Solutions Ltd Detection of cell membrane-associated proteins using membrane fragments displayed on encoded microparticle arrays
US20050277158A1 (en) * 2004-06-10 2005-12-15 Ge Chen Method and kit for donor specific complement-fixing antibodies crossmatch
US7799556B2 (en) * 2004-06-17 2010-09-21 George Dacai Liu System and method for antigen structure-independent detection of antigens captured on antibody arrays
AU2006244486A1 (en) 2005-05-06 2006-11-16 Platypus Technologies, Llc Liquid crystal based analyte detection
CN100354629C (zh) * 2005-10-17 2007-12-12 中国人民解放军第三军医大学第一附属医院 用胶体金标记补体第一成分q亚单位做指示剂的蛋白芯片/微阵列检测系统及检测方法
GB0618496D0 (en) * 2006-09-20 2006-11-01 Common Services Agency Blood typing
JP2008100986A (ja) * 2006-09-21 2008-05-01 Takahiro Ochi C1q結合物質、ならびにその使用
US7964350B1 (en) 2007-05-18 2011-06-21 Applied Biosystems, Llc Sample preparation for in situ nucleic acid analysis
JP2009080019A (ja) 2007-09-26 2009-04-16 Nippon Sekijiyuujishiya 蛍光ビーズを用いた免疫複合体検出による抗体解析法
DE102008045696A1 (de) 2008-09-04 2010-03-11 Drk Blutspendedienst West Ggmbh Granulozyten HNA-3a/b-Antigen
CA2763199A1 (en) 2009-05-29 2010-12-02 The Regents Of The Univeristy Of California B cell signature associated with tolerance in transplant recipients
US20120065092A1 (en) 2010-09-14 2012-03-15 Wai Hobert Fusion analyte cytometric bead assay, and systems and kits for performing the same
US20140249051A1 (en) 2011-08-30 2014-09-04 The Governors Of The University Of Alberta Method and system for abo antibody detection and characterization
WO2014151763A1 (en) 2013-03-14 2014-09-25 The Board Of Trustees Of The Leland Stanford Junior University Methods of detecting donor-specific antibodies and systems for practicing the same
WO2014160376A1 (en) 2013-03-14 2014-10-02 The Board Of Trustees Of The Leland Stanford Junior University Methods of detecting complement fixing and non-complement fixing antibodies and systems for practicing the same

Also Published As

Publication number Publication date
AU2009322607B2 (en) 2015-05-14
US10338080B2 (en) 2019-07-02
EP3460480B1 (en) 2022-11-02
EP3460480A1 (en) 2019-03-27
CA2740192A1 (en) 2010-06-10
CN105866426B (zh) 2018-11-23
US20110281757A1 (en) 2011-11-17
WO2010065425A1 (en) 2010-06-10
JP2012510618A (ja) 2012-05-10
CN105866426A (zh) 2016-08-17
EP2353005B1 (en) 2018-10-03
EP2353005A1 (en) 2011-08-10
JP2015007651A (ja) 2015-01-15
CN102203610A (zh) 2011-09-28
BRPI0923199B8 (pt) 2021-07-27
BRPI0923199B1 (pt) 2020-10-20
JP5792626B2 (ja) 2015-10-14
EP2353005A4 (en) 2012-10-17
CA2740192C (en) 2019-12-31
AU2009322607A1 (en) 2010-06-10

Similar Documents

Publication Publication Date Title
BRPI0923199A2 (pt) métodos e composições para detecção de anticorpos com fixação de complemento.
CY2019004I1 (el) Τροποποιημενα αντισωματα αντι-ιl-23ρ19
IL287311A (en) Antibodies and processes for preparing the same
PT2356153T (pt) Anticorpo biespecífico, de cadeia única, amepxcd3, específico interespécies
PT3072906T (pt) Formulação de anticorpos
BRPI0907237A2 (pt) Anticorpo anti-cldn6
HRP20171011T1 (hr) ANTI-eMET ANTITIJELO
BRPI0906877A2 (pt) Anticorpos anti-trkb aperfeiçoados
IL212175B (en) Muc1* antibodies
BRPI0820298A8 (pt) composições e métodos de anticorpos anti-vegf
PT2853545T (pt) Anticorpo específico para ige
PL3059246T3 (pl) Zmodyfikowany region stały przeciwciała
BRPI0918947A2 (pt) proteína de fusão de anticorpo
EP2358392A4 (en) ANTIBODY FORMULATION
BRPI0820819A2 (pt) Formulação de anticorpos
PT2427212T (pt) Anticorpos anti-cd100 e métodos para utilização dos mesmos
BRPI0820980A2 (pt) Composições e métodos para detecção de tiabs
EP2254911A4 (en) HUMANIZED ANTI-C5aR ANTIBODIES
CR10705A (es) Anticuerpos para linfotoxina-alfa
BRPI0912260A2 (pt) tonalizador.
EP2324359A4 (en) MONOCLONAL ANTIBODY STRO-4
BRPI0813569A2 (pt) Método de inspeção.
IL213116B (en) Antitumor combinations containing antibodies recognizing specifically cd38 and melphalan
BRPI0807991A2 (pt) Anticorpos anti-il-23r elaborados.
DK2344537T3 (da) Bispecifikke anti-vegf/anti-ang-2-antistoffer

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 20/10/2020, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 25/11/2009, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 16A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2856 DE 30-09-2025 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.